Patents Assigned to Cancer Institute
  • 3-(ANILINO)-2-[3-(3-ALKOXY-PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20230064983
    Abstract: Compounds of formula (I) processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: September 22, 2022
    Publication date: March 2, 2023
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Jeremie Xavier G. MORTIER, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Ursula MÖNNING, Michael NIEHUES, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN
  • IL-23R antagonists to reprogram intratumoral T regulatory cells into effector cells
    Patent number: 11591403
    Abstract: Provided by the disclosure are compositions and methods for modulating differentiation of regulatory T cells. In some embodiments, methods include selectively decreasing IL-23R activity and/or IL-23R expression without significantly decreasing IL-12RP activity and/or IL-12RP expression.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: February 28, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Hye-Jung Kim, Jessica M. Sido
  • Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis
    Patent number: 11590213
    Abstract: Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: February 28, 2023
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Harvey Cantor, Hye-Jung Kim, Jianmei Wu Leavenworth
  • HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES
    Publication number: 20230058545
    Abstract: The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., HCK, BTK, LYN, BLK, FRK) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating diseases (e.g., proliferative diseases) in a subject in need thereof).
    Type: Application
    Filed: October 7, 2020
    Publication date: February 23, 2023
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Steven P. Treon, Nathanael S Gay, Sara Jean Buhriage, Guang Yang, Jinhua Wang, Li Tan
  • Inhibitors of EGFR and methods of use thereof
    Patent number: 11584746
    Abstract: The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: February 21, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Dries De Clercq, Jaebong Jang, Pasi Janne, Ciric To, Michael Eck, Eunyoung Park, David Heppner
  • Methods to induce targeted protein degradation through bifunctional molecules
    Patent number: 11583586
    Abstract: The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: February 21, 2023
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: James Bradner, Dennis Buckley, Georg Winter
  • Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
    Patent number: 11584788
    Abstract: The present invention relates to compositions and methods for identifying, assessing, preventing, and treating melanoma. A variety of PD-L1 isoform biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with melanoma status.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: February 21, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: F. Stephen Hodi, Jun Zhou, Gordon J. Freeman, Jingjing Li, Xinqi Wu
  • Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
    Patent number: 11578075
    Abstract: The present application provides bifunctional compounds of Formula (X): or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for protein kinases. The present application also relates to methods for the targeted degradation of one or more protein kinases through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to one or more protein kinases which can be utilized in the treatment of disorders modulated by protein kinases.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: February 14, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James Bradner, Dennis Buckley, Mette Ishoey Rosenbaum, Georg Winter
  • Methods for evaluating tumor cell spheroids using 3D microfluidic cell culture device
    Patent number: 11572590
    Abstract: Provided herein are methods for evaluating tumor cell spheroids in a three-dimensional microfluidic device by determining changes in the relative levels of live cells and dead cells in aliquots cultured under different conditions. Methods described herein allow ex vivo recapitulation of the tumor microenvironment such that the in vivo effectiveness of a test compound in treating tumor tissue may be predicted.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: February 7, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Russell W. Jenkins, David Barbie, Cloud P. Paweletz, Elena Ivanova, Amir Aref
  • Compositions, assays, and methods for direct modulation of fatty acid metabolism
    Patent number: 11567082
    Abstract: This disclosure relates to the surprising and unexpected finding that the well-known cancer protein, Myeloid Cell Leukemia-1 (MCL-1), binds to and modulates the enzymatic activity of Very Long Chain Acyl CoA Dehydrogenase (VLCAD), thereby regulating fatty acid ?-oxidation. This finding is employed in compositions and methods of treating cancer, metabolic diseases, or other conditions characterized by excessive fatty acid ?-oxidation by blocking or reducing the energy production of cells (e.g., cancer) through inhibiting the MCL-1/VLCAD interaction and/or directly inhibiting VLCAD enzymatic activity. In addition, the disclosure features methods for identifying such agents that inhibit the interaction between MCL-1 and VLCAD or that inhibit VLCAD enzymatic activity.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: January 31, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Silvia Escudero
  • DIHYDROOXADIAZINONES
    Publication number: 20230017200
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: July 11, 2022
    Publication date: January 19, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel ELLERMANN, Stefan Nikolaus GRADL, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Philip LIENAU, Christa HEGELE-HARTUNG, Detlev SÜLZLE, Timothy A. LEWIS, Heidi GREULICH, Xiaoyun WU, Matthew MEYERSON, Alex BURGIN
  • SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF
    Publication number: 20230011665
    Abstract: The present invention relates to bispecific compounds, compositions, and methods for treating diseases or conditions mediated by aberrant histone deacety lase 6 (HDAC6) activity.
    Type: Application
    Filed: November 5, 2020
    Publication date: January 12, 2023
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Eric S. Fischer, Yuan Xiong, Katherine Donovan, Nicholas Eleuteri
  • Compositions and methods for treating lysosomal storage diseases and disorders
    Patent number: 11548936
    Abstract: The present invention provides compositions and methods for the treatment or prevention of a lysosomal disease or disorder involving increasing the level, expression, or activity of a metallothionein polypeptide or polynucleotide in the subject.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: January 10, 2023
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, OSPEDALE SAN RAFFAELE S.R.L., DANA-FARBER CANCER INSTITUTE, INC., FONDAZIONE TELETHON
    Inventors: Alessandra Biffi, Eleonora Cavalca
  • Methods and compositions for studying cell evolution
    Patent number: 11547614
    Abstract: The subject matter disclosed herein is generally directed to methods and compositions for tagging cells of interest, tracking evolution of the tagged cells, and recovering the original tagged cells for further study. Specifically, cells are tagged with a DNA construct encoding a barcode sequence comprising a guide sequence. Barcoded cells can then be recovered using a reporter construct having CRISPR target sequences specific for the cell having a barcode of interest.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: January 10, 2023
    Assignees: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Pratiti Bandopadhayay, Rameen Beroukhim, Paul Blainey, David Feldman, Cory Johannessen, Funien Tsai
  • SMALL MOLECULE DEGRADERS OF HELIOS AND METODS OF USE
    Publication number: 20230002397
    Abstract: Disclosed are compounds and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof that may cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds to treat diseases and disorders associated with Helios and which may benefit from Helios degradation.
    Type: Application
    Filed: October 29, 2020
    Publication date: January 5, 2023
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Hu Liu, Tinghu Zhang, Lyn Howard Jones, Jianwei Che
  • IRAK degraders and uses thereof
    Patent number: 11542251
    Abstract: The present invention relates to heterobifunctional compounds (degraders), compositions and methods for treating diseases or conditions mediated by Interleukin Receptor-Associated Kinases (IRAKs).
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: January 3, 2023
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, John Hatcher
  • DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF
    Publication number: 20220409731
    Abstract: Disclosed are bispecific compounds (degraders) that target ALK for degradation.
    Type: Application
    Filed: September 26, 2019
    Publication date: December 29, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, John M. Hatcher, Chelsea E. Powell, Pasi A. Janne
  • Isolation, preservation, compositions and uses of extracts from justicia plants
    Patent number: 11534471
    Abstract: The present disclosure relates to the isolation, preservation, compositions and uses of extracts from a newly discovered species of Justicia plants. The present disclosure also relates to compositions comprising the extracts of the new species of Justicia plant, as well as methods of producing and using such compositions for treating blood disorders and/or for other health, food and industrial uses.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: December 27, 2022
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventor: Wilfred F. Ngwa
  • CRISSCROSS COOPERATIVE SELF-ASSEMBLY
    Publication number: 20220403453
    Abstract: Provided herein, in some embodiments, are methods, compositions and kits for controlling nucleation and assembly of molecular nanostructures, microstructures and macrostructures.
    Type: Application
    Filed: January 14, 2022
    Publication date: December 22, 2022
    Applicants: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: Dionis Minev, Christopher Wintersinger, William M. Shih
  • SELECTIVE HISTONE DEACETYLASE (HDAC) DEGRADERS AND METHODS OF USE THEREOF
    Publication number: 20220401564
    Abstract: The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by aberrant histone deacetylase (HCADC) (e.g., HDAC3) activity.
    Type: Application
    Filed: November 5, 2020
    Publication date: December 22, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Eric S. Fischer, Yuan Xiong, Katherine Donovan, Nicholas Eleuteri